The Validation of a Bioanalytical Method for the Determination of Fluconazole in Human Plasma

A sensitive, specific and robust liquid chromatography-mass spectrometry (LC-MS) method for the determination of fluconazole (α-(2,4-difluorophenyl)-α-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol) in human plasma has been developed and validated. HPLC-UV detection lacked sensitivity and GC-MS analysis was hindered by excessive injection carry-over. The method was successfully developed and validated over a range of 50 ng.mL^?1 to 4000 ng.mL^?1 using protein precipitation. Deuterated fluconazole (d₅) was synthesised ‘in-house’ and used as the LC-MS internal standard. This method has been successfully used to support a bioequivalence clinical study.     

Isocratic Reversed-Phase HPLC for Simultaneous Separation and Determination of Seven Antiepileptic Drugs and Two of their Active Metabolites in Human Plasma

A simple reversed-phase high-performance liquid chromatographic (HPLC) method has been developed for the simultaneous determination of the antiepileptic drugs (AEDs) zonisamide (ZNS), primidone (PRI), lamotrigine (LTG), phenobarbital (PB), phenytoin (PHT), oxcarbazepine (OXC), and carbamazepine (CBZ) and two of their active metabolites, monohydroxycarbamazepine (MHD) and carbamazepine 10,11-epoxide (CBZE) in human plasma. Plasma (100 μL) was pretreated by deproteinization with 300 μL methanol containing 20 μg mL⁻¹ propranolol hydrochloride as internal standard. HPLC was performed on a C₈ column (4.6 mm × 250 mm; particle size 5 μm) with methanol–acetonitrile–0.1% trifluoroacetic acid, 235:120:645 (v/v), as mobile phase at a flow rate of 1.5 mL min⁻¹. ZNS, OXC, and CBZ were monitored by UV detection at 235 nm, and PRI, LTG, MHD, PB, PHT, and CBZE by UV detection at 215 nm. Relationships between response and concentration were linear over the concentration ranges 1–80 μg mL⁻¹ for ZNS, 5–50 μg mL⁻¹ for PRI, 1–25 μg mL⁻¹ for LTG, 1–50 μg mL⁻¹ for MHD, 5–100 μg mL⁻¹ for PB, 1–10 μg mL⁻¹ for CBZE, 0.5–25 μg mL⁻¹ for OXC, 1–50 μg mL⁻¹ for PHT, and 1–25 μg mL⁻¹ for CBZ. Intra-day and inter-day reproducibility were adequate (coefficients of variation were ≤11.6%) and absolute recovery ranged from 95.2 ± 6.13 to 107.7 ± 7.76% for all the analytes; for the IS recovery was 98.69 ± 1.12%. The method was proved to be accurate, reproducible, convenient, and suitable for therapeutic monitoring of the nine analytes.     

Development and Validation of an LC-MS/MS Method for Simultaneous Determination of Short Peptide-Based Drugs in Human Blood Plasma

A novel HPLC-ESI-MS/MS method for simultaneous gonadotropin-releasing hormone (GnRH) analogs and somatostatin analog quantitation was developed and validated. The developed method was successfully applied to pharmacokinetic studies. The sample preparation process included solid-phase extraction (SPE). Effective chromatographic separation of the analytes and internal standard (dalargin) was achieved with a C18 column, using a gradient elution with two mobile phases: 0.1% v/v formic acid (aqueous solution) and 0.1% v/v formic acid (acetonitrile solution). The linearity of the method was demonstrated within a concentration range of 0.5–20 ng/mL, with correlation coefficients between 0.998–0.999 for goserelin, buserelin, triptorelin, and octreotide, respectively. The relative standard deviation (RSD, %) values for method accuracy and precision did not exceed 20% at the lower level of quantitation (LLOQ) or 15% at other concentration levels.     

Rapid RP-LC Method with Fluorescence Detection for Analysis of Fexofenadine in Human Plasma

A rapid and sensitive reversed-phase high-performance liquid chromatographic method for analysis of fexofenadine in human plasma has been developed and optimized. The analytes were extracted from biological samples by solid-phase extraction on hydrophilic–lipophilic balance cartridges. LC separation was performed on a C₁₈ analytical column (125 mm × 4 mm i.d., 5-μm particles) with 42:58 (v/v) acetonitrile–water adjusted to pH 2.7 with 85% orthophosphoric acid as mobile phase. Fluorescence detection was performed with excitation at 230 nm and emission at 290 nm. The total time for chromatographic separation was 7 min. The method was validated in accordance with EU guidelines by analysis of plasma samples fortified with fexofenadine at concentrations between 0.05 and 800 ng mL⁻¹. Calibration plots were linear in this range. Mean recovery was typically 94.03% and the detection limit was 0.05 ng mL⁻¹. The time required for quantitative analysis is shorter than that required by other methods.

     

Rapid RP-LC Method with Fluorescence Detection for Analysis of Fexofenadine in Human Plasma

A rapid and sensitive reversed-phase high-performance liquid chromatographic method for analysis of fexofenadine in human plasma has been developed and optimized. The analytes were extracted from biological samples by solid-phase extraction on hydrophilic–lipophilic balance cartridges. LC separation was performed on a C₁₈ analytical column (125 mm × 4 mm i.d., 5-μm particles) with 42:58 (v/v) acetonitrile–water adjusted to pH 2.7 with 85% orthophosphoric acid as mobile phase. Fluorescence detection was performed with excitation at 230 nm and emission at 290 nm. The total time for chromatographic separation was 7 min. The method was validated in accordance with EU guidelines by analysis of plasma samples fortified with fexofenadine at concentrations between 0.05 and 800 ng mL^?1. Calibration plots were linear in this range. Mean recovery was typically 94.03% and the detection limit was 0.05 ng mL^?1. The time required for quantitative analysis is shorter than that required by other methods.     

A Sensitive and Selective RP-LC Method for the Simultaneous Determination of the Antihypertensive Drugs,Enalapril, Lercanidipine,Nitrendipine and Their Validation

A RP-LC method is presented, which is sensitive and selective for the simultaneous determination of enalapril–lercanidipine and enalapril–nitrendipine binary mixtures in their pharmaceutical dosage forms. The analyte peaks were detected using the LC method with the mobile phase ratio of methanol: water (70:30 v/v, pH 3.0) and a 1.0 mL min⁻¹ flow rate. The detection wavelength was selected at 210 nm using photo diode array detector and column temperature was optimized to 30 °C. Linearity was obtained at different concentration ranges for all working pharmaceutically active compounds between 0.5 and 25 μg mL⁻¹. The proposed methods were extensively validated according to USP 27 requirements and ICH guidelines. The methods were applied to the analysis of pharmaceutical dosage forms containing binary mixtures of enalapril–lercanidipine and enalapril–nitrendipine. Moreover, the proposed methods were applied for the degradation studies of the selected compounds. Degradation studies were conducted using stress conditions such as UV light, acidic and alkaline hydrolysis, oxidation and heat in oven, to evaluate the ability of the separation of the response of standard compounds from their degradation products.

     

A Sensitive and Selective RP-LC Method for the Simultaneous Determination of the Antihypertensive Drugs, Enalapril, Lercanidipine, Nitrendipine and Their Validation

A RP-LC method is presented, which is sensitive and selective for the simultaneous determination of enalapril–lercanidipine and enalapril–nitrendipine binary mixtures in their pharmaceutical dosage forms. The analyte peaks were detected using the LC method with the mobile phase ratio of methanol: water (70:30 v/v, pH 3.0) and a 1.0 mL min^?1 flow rate. The detection wavelength was selected at 210 nm using photo diode array detector and column temperature was optimized to 30 °C. Linearity was obtained at different concentration ranges for all working pharmaceutically active compounds between 0.5 and 25 μg mL^?1. The proposed methods were extensively validated according to USP 27 requirements and ICH guidelines. The methods were applied to the analysis of pharmaceutical dosage forms containing binary mixtures of enalapril–lercanidipine and enalapril–nitrendipine. Moreover, the proposed methods were applied for the degradation studies of the selected compounds. Degradation studies were conducted using stress conditions such as UV light, acidic and alkaline hydrolysis, oxidation and heat in oven, to evaluate the ability of the separation of the response of standard compounds from their degradation products.     

Determination of Penciclovir in Human Plasma Using LC with Fluorescence Detection: Application to a Bioequivalence Study

A novel HPLC method with fluorescence detection and one step sample preparation was developed for the determination of penciclovir in human plasma. Plasma samples (200 μL) were deproteinized by precipitation with 100 μL of perchloric acid and centrifuged. Separation was on an Inertsil ODS-3 column with a mixture of methanol–0.1% orthophosphoric acid as mobile phase. The fluorescence detector was set at Ex 270 nm, Em 375 nm. The assay was selective and linear with a limit of quantification of 0.025 mg L^?1. The mean absolute recovery was 98.1%, while the intra- and inter-day coefficients of variation and percent error values of the assay method were all less than 10%. The assay was successfully applied in a randomized cross-over bioequivalence study of three pharmaceutical products containing 250 mg famciclovir (an oral prodrug of penciclovir) in 18 healthy volunteers.     

Simultaneous RP-LC Determination of Additives in Soft Drinks

A reverse-phase HPLC method for the simultaneous determination of the main artificial sweeteners, preservatives and dyes present in soft drinks is proposed. It involves the use of a 10 μm LiChrosorb RP18 column and a binary eluent consisting of aqueous 0.1 M phosphate buffer (pH 4.0) added with methanol, according to a suitable gradient elution program. Good separations were obtained within less than 20-min run-time, with a satisfactory precision. The sensitivity of spectrophotometric detection was optimised by adopting a wavelength switching technique, thus achieving for all the additives considered detection limits ranging from 0.1 to 3.0 mg L^?1, well below the maximum permitted levels. The method was applied to some commercial soft drinks, whose analysis required minimum pre-treatment before direct injection.     

Simultaneous Determination of Pyridoxine,Meclizine and Buclizine in Dosage Formulations and Human Serum by RP-LC

Rapid liquid chromatographic procedures for analytical quality control of pharmaceutical preparations and human serum containing antihistamine drugs, meclizine and buclizine alone or in combination with pyridoxine are proposed, using acetonitrile:water (80:20) as a mobile phase (pH adjusted to 2.6), methylparaben as internal standard and UV detection was made at 230 nm. The results obtained showed a good agreement with the declared content. The method shows good linearity in the range of 30–10,000 ng mL⁻¹ for pyridoxine and 25–10,000 ng mL⁻¹ for meclizine and buclizine serum concentrations with a correlation coefficient 0.9999 (inter- and intra-day CV < 3.91%). The recovery was >97.8%. The proposed method may be used for the quantitative analysis of meclizine and buclizine alone or in combination with pyridoxine from raw materials, in bulk drugs, dosage formulations and in serum.

     

Simultaneous Determination of Pyridoxine, Meclizine and Buclizine in Dosage Formulations and Human Serum by RP-LC

Rapid liquid chromatographic procedures for analytical quality control of pharmaceutical preparations and human serum containing antihistamine drugs, meclizine and buclizine alone or in combination with pyridoxine are proposed, using acetonitrile:water (80:20) as a mobile phase (pH adjusted to 2.6), methylparaben as internal standard and UV detection was made at 230 nm. The results obtained showed a good agreement with the declared content. The method shows good linearity in the range of 30–10,000 ng mL^?1 for pyridoxine and 25–10,000 ng mL^?1 for meclizine and buclizine serum concentrations with a correlation coefficient 0.9999 (inter- and intra-day CV < 3.91%). The recovery was >97.8%. The proposed method may be used for the quantitative analysis of meclizine and buclizine alone or in combination with pyridoxine from raw materials, in bulk drugs, dosage formulations and in serum.     

Development of an SPE Method Using Ionic Liquid-Based Monolithic Column for On-Line Cleanup of Human Plasma and Simultaneous Determination of Five Steroid Drugs

An 1-vinyl-3-hexyl imidazolium bromide ionic liquid-based monolithic column was prepared via in situ free radical polymerization, which was used as the sorbent of on-line solid phase extraction. The prepared material was characterized by scanning electron microscopy, nitrogen adsorption–desorption instrument and mercury intrusion porosimetry, respectively, and the results showed that the homemade monolith occupied relatively uniform porous structure and high-specific surface area of 212.53 m² g^?1. On-line solid phase extraction–high-performance liquid chromatography was performed to quantitatively analyze five steroid drugs, including betamethasone, norgestrel, halcinonide, beclomethasone dipropionate and testosterone propionate in human plasma. The determination procedure was carried out following the optimization of the mobile phase composition. Methodological validation showed that correlation coefficients of the linear regressions were in the range of 0.9989–0.9992; the values of relative standard deviation for precision were in the range of 1.39–6.15% for intra-day and 0.32–6.34% for inter-day, respectively; the values of accuracy expressed by recovery were in the range of 99.02–101.98, 93.27–102.89, 102.79–104.01, 100.04–102.61 and 100.77–102.44% for the five drugs in order, respectively; the values of relative standard deviation for repeatability calculated according to retention times and peak areas of the five drugs were in the ranges of 0.28–0.76% (n?=?5) and 0.84–2.63% (n?=?5), respectively. The results showed that the polymer monolithic column was feasible for an on-line solid phase extraction column, exhibiting good selectivity and high permeability.     

LC-MS-MS Method for Simultaneous Determination of Icariin and Its Active Metabolite Icariside II in Human Plasma

An LC-MS-MS method was revised and validated for simultaneous determination of icariin and its active metabolite icariside II in human plasma. The analytes and daidzein (IS) were extracted by liquid–liquid extraction and analyzed by LC-MS-MS. The separation was performed by a Zorbax SB-C₁₈ column (3.5 μm, 2.1 × 100 mm) with an isocratic mobile phase consisting of methanol–water–formic acid (65:35:0.035, v/v/v) at a flow rate of 0.25 mL min^?1. Detection was performed on a triple quadrupole tandem mass spectrum by multiple reaction monitoring mode using the electrospray ionization technique in positive mode. The method had lower limits of quantitation 0.2 and 0.1 ng mL^?1 for icariin and icariside II, respectively, using 500 μL plasma sample. The linear calibration curves were obtained in the concentration range of 0.2–100 ng mL^?1 for icariin and 0.1–100 ng mL^?1 for icariside II. The RSD values of intra- and inter-day precision calculated from quality control (QC) samples were less than 7.2% for icariin and less than 6.5% for icariside II. The accuracy as determined from QC samples was within 3.8% for each analyte. The method has been applied to determine and evaluate the pharmacokinetic of icariin and its metabolite icariside II in volunteers following oral administration of icariin and extract of Epimedium, respectively.     

Simultaneous RP-LC Determination of Artesunate and Amodiaquine in Pharmaceutical Preparations

A simple, fast and precise reversed phase liquid chromatographic method was developed for the simultaneous determination of artesunate (AS) and amodiaquine (AD) in combined pharmaceutical dosage form. Chromatographic separation of the two drugs was performed on a BDS Hypersil C18, 100 mm × 4.6 mm, 3 μm particle size column as stationary phase with a mobile phase comprising of phosphate buffer (pH 3.0 with orthophosphoric acid) and acetonitrile in the proportion of 50:40 (v/v), at a flow rate of 0.8 mL min^?1 and UV detection at wavelength 210 nm for AS and 300 nm for AD using photo diode array detection. The proposed method was validated for specificity, accuracy, linearity, range, precision and was successfully applied to the simultaneous determination of AS and AD in the combined fixed dosage form without any excipient’s interference.     

Simultaneous Determination of Tranexamic Acid and Losartan Potassium in Dosage Formulations and Human Serum by RP-LC

Rapid liquid chromatographic procedure for analytical quality control of pharmaceutical preparations and human serum containing drugs, tranexamic acid together with losartan potassium are proposed, using acetonitrile: water (50:50), adjusting pH to 2.6 with phosphoric acid as a mobile phase, UV detection at 205 nm and propylparaben sodium was used as internal standard. The results obtained showed a good agreement with the declared contents. The method shows good linearity in the range of 40–10,000 ng mL^?1 for tranexamic acid serum concentrations with a correlation coefficient 0.9999 (inter- and intra-day CV <3.18) and in the range 5–10,000 ng mL^?1 for losartan potassium serum concentrations with a correlation coefficient 0.9999 (inter- and intra-day CV <3.61). The recovery was >97.8%. The proposed method may be used for the quantitative analysis of tranexamic acid and losartan potassium alone or in combination from raw materials, in bulk drugs, dosage formulations and in serum.     

液相色谱-串联质谱法同时检测饲料中7种精神类药物

建立了液相色谱-串联质谱同时检测饲料样品中7种精神类药物(硝西泮、奥沙西泮、氯丙嗪、异丙嗪、地西泮、奋乃静、硫利达嗪)的方法.通过对提取溶剂、净化等预处理条件及LC-MS/MS 分析条件的优化,可以同时检测饲料中7种违禁精神类药物.饲料样品经乙腈/水(9:1, V/V)提取后,过MCX固相萃取柱净化,氮吹至干,用1 mL乙腈/水(2:8, V/V)溶解后测定,采用SRM模式进行定性与定量分析.7种精神类药物在饲料中的回收率为53.9%～110.2%; 相对标准偏差为3.4%～18.4%;硝西泮、奥沙西泮、氯丙嗪、异丙嗪的检出限为1.0 ng/g;对地西泮、奋乃静、硫利达嗪的检出限为5.0 ng/g.结果表明,本方法可用于饲料中7种精神类药物的测定.     

LC-APCI-MS法同时分离测定人体血浆中的精氨酸及二甲基精氨酸的含量

建立了简单、灵敏和快速分离测定人体血浆中L-精氨酸(ARG)、不对称二甲基精氨酸(ADMA)和对称二甲基精氨酸(SDMA)的等度高效液相色谱-质谱联用方法.采用选择性离子检测(SIM)和大气压化学电离离子化(APCI),L-高精氨酸作内标,整个方法测定时间在5min以内.ARG,ADMA和SDMA的分析限均为0.2μmol/L,日间和日内测定的精密度分别为2.9%～6.7%和2.1%～5.2%,标准加入回收率为94.0%～105.0%.采用上述方法测定人体血浆中的精氨酸及二甲基精氨酸的含量,结果令人满意.     

GC-MS定量测定人血浆中NBP的方法学研究

NBP是国内1类新药.由国家药品监督管理局批准在我院进行Ⅰ期临床研究.测定健康男性受试者口服NBP后的血药浓度,了解NBP的药代动力学特点,将为建立NBP安全有效的给药方案提供理论依据.     

LC-ESI-MS Method for the Determination of Mizolastine in Human Plasma

A sensitive and rapid liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) method has been developed and validated for the determination of mizolastine in human plasma using dipyridamole as the internal standard (I.S.). Plasma samples were simply pretreated with methanol for deproteinization. Chromatographic separation was performed on an Agilent Zorbax C₁₈ column with a mobile phase of 10 mM ammonium acetate buffer containing 0.1% formic acid–methanol (20:80, v/v) at a flow rate of 1 mL min⁻¹. The electrospray ionization (ESI) interface was employed in a single quadrupole mass spectrometer. The analytes were protonated in the positive ESI interface and detected in single ion monitoring (SIM) mode. Chromatographic separation was achieved in less than 3.5 min. The linearity was established over the range of 0.5–600 ng mL⁻¹. The lower limited of quantification (LLOQ) of the method was 0.5 ng mL⁻¹. The intra- and inter-run standard deviations were both less than 11.2%. The method was applied to study the pharmacokinetics of the mizolastine sustained-release tablets in healthy volunteers.     

Simultaneous Separation and Determination of Lamivudine and Zidovudine in Pharmaceutical Formulations Using the HPTLC Method

Abstract

A high-performance thin-layer chromatographic method (HPTLC) for the simultaneous determination of lamivudine and zidovudine in a binary mixture has been developed. The method developed was based on HPTLC separation of the two drugs followed by densitometric measurements of spots at 276 and 271 nm for lamivudine and zidovudine, respectively. Separation was carried out on Merck HPTLC silica-gel 60 F₂₅₄ plates, using toluene/chloroform/methanol (1:6:3 v:v) as the mobile phase. Validation of the method was performed based on The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines in terms of linearity, accuracy, precision, limit of detection, limit of quantification, and robustness. Second-order polynomial equations were obtained for the regression line in the ranges of 250–1400 and 250–1700 ng/spot for lamivudine and zidovudine respectively. Correlation coefficient (r) values were 0.9998 for both analytes. The method provides sufficient accuracy as indicated by recovery percentages given for lamivudine and zidovudine. For system precision study, the low coefficient of variation values (<2%) for both lamivudine and zidovudine ensured reproducible performance of the instrument. In the method precision study, coefficients of variation <2% were obtained, which showed that the proposed method provides acceptable intraday and interday variation. The detection and quantification limits and were 3.06 and 9.28 ng/spot for lamivudine and 3.34 and 10.13 ng/spot for zidovudine, respectively. Parameters such as mobile-phase composition, volume of mobile phase, time from spotting to development, and time from development to scanning were employed while testing for robustness of the method, and the standard deviation of peak areas was calculated for each parameter. The low coefficient of variation values indicated the robustness of the method. Statistical manipulation did not show any significant effect of one parameter over the others on the robustness of the method.